These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease.
    Author: Sánchez-Cano D, Callejas-Rubio JL, Ortego-Centeno N.
    Journal: J Clin Rheumatol; 2008 Apr; 14(2):92-3. PubMed ID: 18391678.
    Abstract:
    Wegener granulomatosis is an autoimmune disorder with a double spectrum. Vasculitic manifestations are at one end of it, whereas granulomatous ones are at the other. Rituximab (RTX) is a chimeric monoclonal antibody that has been successfully used in this condition. However, the granulomatous forms have been reported to show a tendency to be less responsive to RTX than the vasculitic disease. We present 4 cases of predominantly Wegener granulomatosis that responded positively to RTX.
    [Abstract] [Full Text] [Related] [New Search]